Targeting adenoviruses with factor X-single-chain antibody fusion proteins

Human Gene Therapy

Volumn 21, Issue 6, 2010, Pages 739-749

  Chen, Christopher Y ^a   May, Shannon M ^b,c   Barry, Michael A ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Translational Immunovirology Program   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 10; BREAST CANCER RESISTANCE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADENOVIRUS 5; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION; NONHUMAN; PROTEIN EXPRESSION;

1-CARBOXYGLUTAMIC ACID; ADENOVIRIDAE; FACTOR X; GENETIC VECTORS; HEPATOCYTES; HUMANS; LIGANDS; PROTEINS; SINGLE-CHAIN ANTIBODIES;

ADENOVIRIDAE;

EID: 77954986093     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.190     Document Type: Article

References (25)

1. Alba, R., Bradshaw, A.C., Parker, A.L., Bhella, D., Waddington, S.N., Nicklin, S.A., Van Rooijen, N., Custers, J., Goudsmit, J., Barouch, D.H., McVey, J.H., and Baker, A.H. (2009). Identification of coagulation factor (F)X binding sites on the adeno-virus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer. Blood 114, 965-971.
2. Barbas, C.F., III, Burton, D.R., Scott, J.K., and Silverman, G.J. (2001). In Phage Display: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) pp. 953-964.
3. Bosher, J.M., Williams, T., and Hurst, H.C. (1995). The devel-opmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc. Natl. Acad. Sci. U.S.A. 92, 744-747.
4. Campos, S.K., and Barry, M.A. (2006). Comparison of adenovi-rus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 349, 453-462.
5. Campos, S.K., Parrott, M.B., and Barry, M.A. (2004). Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol. Ther. 9, 943-955.
6. Glasgow, J.N., Mikheeva, G., Krasnykh, V., and Curiel, D.T. (2009). A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One 4, e8355.
7. Habib, N.A., Mitry, R., Seth, P., Kuppuswamy, M., Doronin, K., Toth, K., Krajcsi, P., Tollefson, A.E., and Wold, W.S. (2002). Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 9, 651-654.
8. Hasegawa, K., Hu, C., Nakamura, T., Marks, J.D., Russell, S.J., and Peng, K.W. (2007). Affinity thresholds for membrane fusion triggering by viral glycoproteins. J. Virol. 81, 13149-13157.
9. Hedley, S.J., Auf Der Maur, A., Hohn, S., Escher, D., Barberis, A., Glasgow, J.N., Douglas, J.T., Korokhov, N., and Curiel, D.T. (2006). An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 13, 88-94.
10. Hellstrom, I., Goodman, G., Pullman, J., Yang, Y., and Hell-strom, K.E. (2001). Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 61, 2420-2423.
11. Hirschmann-Jax, C., Foster, A.E., Wulf, G.G., Nuchtern, J.G., Jax, T.W., Gobel, U., Goodell, M.A., and Brenner, M.K. (2004). A distinct "side population'' of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 101, 14228-14233.
12. Kalyuzhniy, O., Di Paolo, N.C., Silvestry, M., Hofherr, S.E., Barry, M.A., Stewart, P.L., and Shayakhmetov, D.M. (2008). Adeno-virus serotype 5 hexon is critical for virus infection of hepato-cytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483-5488.
13. Li, H.J., Everts, M., Pereboeva, L., Komarova, S., Idan, A., Curiel, D.T., and Herschman, H.R. (2007). Adenovirus tumor targeting and hepatic untargeting by a coxsackie=adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res. 67, 5354-5361.
14. Nakamura, T., Peng, K.W., Harvey, M., Greiner, S., Lorimer, I.A., James, C.D., and Russell, S.J. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Bio-technol. 23, 209-214.
15. Noureddini, S.C., Krendelshchikov, A., Simonenko, V., Hedley, S.J., Douglas, J.T., Curiel, D.T., and Korokhov, N. (2006). Generation and selection of targeted adenoviruses embodying optimized vector properties. Virus Res. 116, 185-195.
16. Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J.H., Nicklin, S.A., and Baker, A.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
17. Parrott, M.B., Adams, K.E., Mercier, G.T., Mok, H., Campos, S.K., and Barry, M.A. (2003). Metabolically biotinylated adenovirus for cell-targeting, ligand screening, and vector purification. Mol. Ther. 8, 689-702.
18. Pereboev, A.V., Asiedu, C.K., Kawakami, Y., Dong, S.S., Black-well, J.L., Kashentseva, E.A., Triozzi, P.L., Aldrich, W.A., Curiel, D.T., Thomas, J.M., and Dmitriev, I.P. (2002). Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9, 1189-1193.
19. Rebetz, J., Na, M., Su, C., Holmqvist, B., Edqvist, A., Nyberg, C., Widegren, B., Salford, L.G., Sjogren, H.O., Arnberg, N., Qian, Q., and Fan, X. (2009). Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence. PLoS One 4, e8484.
20. Schier, R., Bye, J., Apell, G., McCall, A., Adams, G.P., Malmqvist, M., Weiner, L.M., and Marks, J.D. (1996). Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255, 28-43.
21. Shashkova, E.V., Doronin, K., Senac, J.S., and Barry, M.A. (2008). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with on-colytic adenovirus. Cancer Res. 68, 5896-5904.
22. Shashkova, E.V., May, S.M., Doronin, K., and Barry, M.A. (2009). Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol. Ther. 17, 2121-2130.
23. Tang, Y., Lou, J., Alpaugh, R.K., Robinson, M.K., Marks, J.D., and Weiner, L.M. (2007). Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179, 2815-2823.
24. Vigant, F., Descamps, D., Jullienne, B., Esselin, S., Connault, E., Opolon, P., Tordjmann, T., Vigne, E., Perricaudet, M., and Benihoud, K. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 16, 1474-1480.
25. Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., Pink, R., Buckley, S.M., Greig, J.A., Denby, L., Custers, J., Morita, T., Francischetti, I.M., Monteiro, R.Q., Barouch, D.H., van Rooijen, N., Napoli, C., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409.